Julie Scallen

Ms. Scallen’s recent transactions include representing: 

• AMAG Pharmaceuticals, Inc. in its US$1.025 billion reverse merger with Lumara Health, a specialty pharmaceutical company
• Atrium Medical Corporation, a healthcare manufacturer of medical device technologies, in its US$680 million acquisition by Getinge AB
• Boston Scientific Corporation in its US$300 million acquisition of Apama Medical, Inc., a developer of radio-frequency balloon catheters
• Boston Scientific Corporation in its US$435 million acquisition of Symetis SA, a Swiss structural heart company
• Boston Scientific Corporation in its US$210 acquisition of EndoChoice Holdings, Inc., a developer of devices for gastrointestinal conditions
• Boston Scientific Corporation in its equity investment in, and sales and marketing alliance with, Preventice Solutions, a developer of mobile health solutions
• Boston Scientific Corporation in its US$415 million acquisition of the Interventional Division of Bayer AG, a global pharmaceutical and chemical company
• Boston Scientific Corporation in its acquisition of StarMedTec GmbH, a German medical laser systems company
• Boston Scientific Corporation in its US$275 million acquisition of the Electrophysiology Division of C.R. Bard, a company engaged in the provision of devices for the diagnosis and treatment of cardiac arrhythmias
• Boston Scientific Corporation in its US$1.35 billion acquisition of Cameron Health, Inc., a company that develops implantable cardioverter defibrillators
• Boston Scientific Corporation in its US$425 million acquisition of Vessix Vascular, Inc., a developer of a renal denervation system
• Claros Diagnostics, Inc., a developer of a microfluidics-based test system, in its US$49 million sale to Opko Health, Inc.
• Cimpress N.V., in its €91 million acquisition of Exagroup SAS, a French web-to-print company
• Micronetics, Inc., a manufacturer of microwave and radio frequency components, in its US$75 million sale to Mercury Computer Systems, Inc.